U.S. Markets closed

Diplomat Pharmacy (DPLO) Catches Eye: Stock Jumps 9.4%

Zacks Equity Research

Diplomat Pharmacy, Inc. DPLO was a big mover last session, as the company saw its shares rise above 9% on the day. The stock rallied after the company announced that it completed the acquisition of Houston, TX-based specialty pharmacy, and infusion services company, Affinity Biotech, Inc. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $12.50 to $14.19 in the past one-month time frame.

In the last 30 days, the company has seen five downward estimate revisions and the Zacks Consensus Estimate also moved lower, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.       

Diplomat Pharmacy currently carries a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.

Diplomat Pharmacy, Inc. Price

 

Diplomat Pharmacy, Inc. Price | Diplomat Pharmacy, Inc. Quote

A better-ranked stock from the broader Retail-Wholesale sector is Advance Auto Parts, Inc. AAP, which holds a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Is DPLO going up? Or down? Predict to see what others think: Upor Down

The Best Place to Start Your Stock Search

Today, you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Advance Auto Parts Inc (AAP): Free Stock Analysis Report
 
Diplomat Pharmacy, Inc. (DPLO): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research